MPNs

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

Dr Komrokji explains how the IPSS-M improves prognostic precision in MDS but cautions that upstaging alone should not automatically drive treatment escalation.

The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a PDUFA date of July 6, 2026.

TP53 mutations represent a critical high-risk factor across myeloid diseases, necessitating immediate transplant referral as the only curative option due to the limited durability of current standard therapies such as venetoclax and hypomethylating agents.

The combination of selinexor and ruxolitinib achieved a statistically significant and sustained reduction in spleen volume compared with ruxolitinib alone in patients with JAK inhibitor treatment-naïve myelofibrosis, though symptom improvement was comparable across both arms.

Dr David Sallman tailors venetoclax dosing based on transplant candidacy, using 21-day induction for transplant-eligible patients followed by rapid tapering upon response.

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David Sallman, MD. Proceeding directly to transplant in patients with TP53-mutated disease may lead to optimal outcomes.

Effectively assessing anemia in myelofibrosis goes beyond hemoglobin levels, and should focus on symptoms, daily function, and quality of life to guide treatment.

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising.

Overcoming ESA-refractory MDS involves greater use of targeted agents based on the patient's molecular profile.

PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.

The FDA has granted a priority review and accepted the NDA for rusfertide in PV.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

During a live event, Edward Pearson, MD, and participants discussed their approaches to using JAK inhibitors in myelofibrosis based on blood cell counts.

t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies that extend life and preserve quality of life.

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better posttransplant survival despite TP53 mutations.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options.

A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes.